Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | HPGDS | O60760 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | TYK2 | P29597 | 1/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3767339 | 0.85 | RAB9A (0.51) | KMT2AMAPK14HPGDSGAANPC1 | |
| SCHEMBL19520435 | 0.84 | LMNA (0.56) | NPC1RAB9A | |
| SCHEMBL13213725 | 0.84 | POLB (0.50) | POLBKMT2AMAPK14HPGDSPKM | |
| SCHEMBL14699724 | 0.83 | KMT2A (0.54) | POLBKMT2AMAPK14HPGDSGAA | |
| SCHEMBL14938017 | 0.81 | OXTR (0.57) | KMT2AHPGDS | |
| SCHEMBL3268236 | 0.80 | KMT2A (0.57) | POLBKMT2AMAPK14HPGDSNPC1 | |
| SCHEMBL395662 | 0.80 | TYK2 (0.55) | KMT2AMAPK14TYK2NPC1RAB9A | |
| SCHEMBL13137735 | 0.79 | MAPK8 (0.48) | POLBKMT2AMAPK14HPGDSMAPK8 | |
| SCHEMBL13235065 | 0.79 | KMT2A (0.73) | POLBKMT2AMAPK14NPC1RAB9A | |
| SCHEMBL3892152 | 0.78 | HPGDS (0.49) | POLBKMT2AMAPK14HPGDSMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314131-B2 | Triazole fused heteroaryl compounds and methods of use thereof | AMGEN INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-8101612-B2 | N-3-isoxazolyl-4-methyl-3-(1-((1-methylethyl)oxy)-6-phthalazinyl)benzamide; p38 kinase inhibitor; antiinflammatory, analgesic agent; rheumatoid arthritis, osteoporosis, leukemia, psoriasis, Crohn's disease, rhinitis, ulcerative colitis, dermatitis, asthma, Alzheimer's disease, type I and II diabetes | AMGEN INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100292234-A1 | TRIAZOLE FUSED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-7700593-B2 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | AMGEN INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20080161303-A1 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | AMGEN INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080119468-A1 | Phthalazine, aza-and diaza-phthalazine compounds and methods of use | AMGEN INC. (US) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292234-A1 | TRIAZOLE FUSED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | MAPK1, MAPK3, CNKSR1 | POLB 2612/4885KMT2A 3793/4885MAPK14 46/4885 |
| US-20080119468-A1 | Phthalazine, aza-and diaza-phthalazine compounds and methods of use | DAPK2, CDK2, DAPK1 | POLB 2547/4885KMT2A 260/4885MAPK14 293/4885 |
| US-20080161303-A1 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | MAPK1, MAP3K1, MAP3K7 | POLB 2333/4885KMT2A 3439/4885MAPK14 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.